Review provides nuanced assessment of CBD for epilepsy: modest benefits, notable drug interactions, and a gap between evidence and public belief
While purified CBD shows modest but significant seizure improvement in Dravet and Lennox-Gastaut syndromes, important drug interactions (especially with clobazam and valproate) and a gulf between evidence and public expectations complicate the picture.
Quick Facts
What This Study Found
Only purified CBD formulations have been rigorously evaluated in controlled trials, showing modest but significant improvements in motor seizures. Key adverse effects include diarrhea, somnolence, and reduced appetite, with up to 1 in 23 risk of serious adverse events. Significant drug interactions: valproate increases hepatotoxicity risk; clobazam interaction contributes to somnolence and potentially efficacy.
Key Numbers
Up to 1 in 23 risk of serious adverse events from CBD. Drug interactions with valproate (hepatotoxicity) and clobazam (somnolence, efficacy). Only purified CBD has been rigorously tested in controlled trials.
How They Did This
Review summarizing current knowledge of cannabinoids for epilepsy, including controlled trial data for purified CBD, animal model evidence, drug interactions, and the gap between evidence and public perception.
Why This Research Matters
There is significant public enthusiasm for cannabis-based treatments for epilepsy that outpaces the actual evidence. This review helps calibrate expectations while acknowledging genuine therapeutic value.
The Bigger Picture
The gap between public expectations (fueled by media and anecdote) and the actual evidence base for cannabinoids in epilepsy is a significant challenge for clinicians and policymakers.
What This Study Doesn't Tell Us
No comparative effectiveness studies between CBD and other antiseizure medications; unclear how much of CBD's benefit is from direct anticonvulsant effect vs. clobazam interaction; limited evidence for THC-containing products.
Questions This Raises
- ?How much of CBD's seizure benefit comes from its interaction with clobazam rather than direct anticonvulsant effects?
- ?Should THC-containing products be studied for epilepsy despite mental health risks?
Trust & Context
- Key Stat:
- Up to 1 in 23 patients experience serious adverse events; significant interactions with clobazam and valproate
- Evidence Grade:
- Review synthesizing controlled trial evidence with clinical context and drug interaction data.
- Study Age:
- Published in 2020.
- Original Title:
- A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?
- Published In:
- Neuropharmacology, 170, 107861 (2020)
- Authors:
- Cross, J Helen(3), Cock, Hannah
- Database ID:
- RTHC-02486
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How effective is CBD for epilepsy?
Purified CBD has shown modest but statistically significant improvements in motor seizures in rigorous controlled trials for Dravet and Lennox-Gastaut syndromes. "Modest" means the effect is real but not dramatic for most patients.
What are the main safety concerns?
Key concerns include drug interactions with valproate (increased liver toxicity risk) and clobazam (increased somnolence), diarrhea, and up to a 1-in-23 chance of serious adverse events. The clobazam interaction also complicates understanding of whether CBD works directly or through altering clobazam levels.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02486APA
Cross, J Helen; Cock, Hannah. (2020). A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?. Neuropharmacology, 170, 107861. https://doi.org/10.1016/j.neuropharm.2019.107861
MLA
Cross, J Helen, et al. "A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?." Neuropharmacology, 2020. https://doi.org/10.1016/j.neuropharm.2019.107861
RethinkTHC
RethinkTHC Research Database. "A perspective on cannabinoids for treating epilepsy: Do they..." RTHC-02486. Retrieved from https://rethinkthc.com/research/cross-2020-a-perspective-on-cannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.